Previous 10 | Next 10 |
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever RNA editing proof-of-mechanism in humans Selection of clinical candidate for GalNAc-siRNA INHBE program in obesity now planned for 3Q 2024, ah...
2024-01-03 21:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
CAMBRIDGE, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that Paul Bolno, MD, MBA, President and Chief Executive Offi...
2023-12-19 10:11:12 ET Penny Stocks and Preparing for 2024 As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023’s ups and downs; maybe not. For those interested in penny stocks, the high-risk but potentially...
2023-12-18 11:24:00 ET Summary Wave Life Sciences Ltd. raised $100 million in a discounted public offering, causing a decline in their stock price. The market reaction may have been incorrect, as the company has positive proof of concept data and major partnerships with Takeda and...
FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024 Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are importan...
2023-12-13 16:59:17 ET Gainers: Codexis ( CDXS ) +16% . Nubia Brand International ( NUBI ) +13% . E.W. Scripps Company ( SSP ) +5% . WAVE Life Sciences ( WVE ) +5% . Losers: Amtech Systems ( ASYS ) -31% . Mont...
2023-12-08 10:36:37 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences falls sharply on pricing $100M secondary offering Wa...
2023-12-07 10:00:03 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom For further details see: Organovo, Fort...
2023-12-07 07:16:38 ET More on Wave Life Sciences Wave Life Sciences Ltd. (WVE) Q3 2023 Earnings Call Transcript Wave Life Sciences: Excellent Early Data, Major Collaborations, Needs Cash Wave Life Sciences proposes public offering of ordinary shares and pre-funded w...
News, Short Squeeze, Breakout and More Instantly...
Wave Life Sciences Ltd. Company Name:
WVE Stock Symbol:
NASDAQ Market:
2024-05-15 07:00:05 ET Tiago Fauth from Wells Fargo issued a price target of $11.00 for WVE on 2024-05-15 05:53:00. The adjusted price target was set to $11.00. At the time of the announcement, WVE was trading at $5.84. WVE currently trades -24.58% versus its 52 week hig...
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unloc...
RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, ...